Ülke: ABD
Dil: İngilizce
Kaynak: NLM (National Library of Medicine)
DOCETAXEL ANHYDROUS (UNII: 699121PHCA) (DOCETAXEL ANHYDROUS - UNII:699121PHCA)
Northstar RxLLC
DOCETAXEL ANHYDROUS
DOCETAXEL ANHYDROUS 20 mg in 1 mL
PRESCRIPTION DRUG
New Drug Application
DOCETAXEL- DOCETAXEL INJECTION, SOLUTION NORTHSTAR RXLLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DOCETAXEL INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DOCETAXEL INJECTION DOCETAXEL INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1996 WARNING:TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, AND FLUID RETENTION _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING_ TREATMENT-RELATED MORTALITY INCREASES WITH ABNORMAL LIVER FUNCTION, AT HIGHER DOSES, AND IN PATIENTS WITH NSCLC AND PRIOR PLATINUM-BASED THERAPY RECEIVING DOCETAXEL AT 100 MG/M ( 5.1) SHOULD NOT BE GIVEN IF BILIRUBIN > ULN, OR IF AST AND/OR ALT > 1.5 × ULN CONCOMITANT WITH ALKALINE PHOSPHATASE > 2.5 × ULN. LFT ELEVATIONS INCREASE RISK OF SEVERE OR LIFE-THREATENING COMPLICATIONS. OBTAIN LFTS BEFORE EACH TREATMENT CYCLE ( 8.6) SHOULD NOT BE GIVEN IF NEUTROPHIL COUNTS ARE < 1500 CELLS/MM . OBTAIN FREQUENT BLOOD COUNTS TO MONITOR FOR NEUTROPENIA ( 4) SEVERE HYPERSENSITIVITY, INCLUDING VERY RARE FATAL ANAPHYLAXIS, HAS BEEN REPORTED IN PATIENTS WHO RECEIVED DEXAMETHASONE PREMEDICATION. SEVERE REACTIONS REQUIRE IMMEDIATE DISCONTINUATION OF DOCETAXEL INJECTION AND ADMINISTRATION OF APPROPRIATE THERAPY ( 5.4) CONTRAINDICATED IF HISTORY OF SEVERE HYPERSENSITIVITY REACTIONS TO DOCETAXEL OR TO DRUGS FORMULATED WITH POLYSORBATE 80 ( 4) SEVERE FLUID RETENTION MAY OCCUR DESPITE DEXAMETHASONE ( 5.5) INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: BREAST CANCER (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1) NON-SMALL CELL LUNG CANCER (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2) HORMONE REFRACTORY PROSTATE CANCER (HRPC): with Belgenin tamamını okuyun